drugset / Trial / NCT03976245
Advanced Therapeutics in Rheumatoid Arthritis (RA)
Phase 4
Recruiting
144 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Academic Medical Organization of Southwestern Ontario · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
Timeline
- Start
- 2020-03-01
- Primary completion
- 2025-03
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Etanercept | Protein / enzyme biologic | 50 mg | Subcutaneous |
| Comparator | Tofacitinib | Small molecule | 5 mg | Oral |